Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein II(b)/III(a) receptor antagonist

European Journal of Pharmacology

Volumn 367, Issue 2-3, 1999, Pages 275-282

  Banno, Hitoshi ^b   Kawazura, Hiroshi ^a,b   Yutaka, Takanori ^b   Sakuma, Noriko ^b   Kitamori, Takashi ^b   Hosoya, Junko ^b   Kibayashi, Kenji ^b   Yamashita, Hiroyuki ^c   Umemura, Kazuo ^a   Nakashima, Mitsuyoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Institute of Biological Science   (Japan)

^c Mitsui Chemicals Mobara 297 0017   (Japan)

Author keywords

Arterial thrombosis model; Bleeding time; Glycoprotein II(b) III(a) receptor antagonist; MS 180; Platelet aggregation; Platelet release reaction

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ETHYL [6 [4 (MORPHOLINOFORMIMIDOYL)BENZAMIDO] 3,4 DIHYDRO 2H 1 BENZOPYRAN 3 YL]ACETATE HYDROCHLORIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG EFFECT; GUINEA PIG; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOGENESIS; THROMBOSIS;

ACETIC ACIDS; ADENOSINE DIPHOSPHATE; ANESTHESIA; ANIMALS; ASPIRIN; BLEEDING TIME; BLOOD PLATELETS; COLLAGEN; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; GLYCOPROTEINS; GUINEA PIGS; HUMANS; MORPHOLINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING;

EID: 0032970858     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00937-6     Document Type: Article

References (40)

1. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308:1994;81-106.
2. Aoki T., Cox D., Senzaki K., Seki J., Tanaka A., Takasugi H., Motoyama Y. The anti-platelet and anti-thrombotic effects of FK633, a peptide-mimetic GPIIB/IIIA antagonist. Thromb. Res. 81:1966;439-450.
3. Bostwick J.S., Kasiewski C.J., Chu V., Klein S.I., Sabatino R.D., Perrone M.H., Dunwiddie C.T., Cook J.J., Leadley R.J. Jr. Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist. Thromb. Res. 82:1996;495-507.
4. 2. Thromb. Res. 88:1997;109-125.
5. a peptide. J. Biol. Chem. 266:1991;1415-1421.
6. a antagonist, sibrafiban, in patients after an acute coronary syndrome. Results of the TIMI 12 Trial. Circulation. 97:1998;340-349.
7. a receptors as an antithrombotic strategy. Circulation. 92:1995;2373-2380.
8. a antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb. Haemost. 78:1997;730-735.
9. a inhibitors: 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J. Pharmacol. Exp. Ther. 278:1996;62-73.
10. Duggan M.E., Naylor-Olsen A.M., Perkins J.J., Anderson P.S., Chang C.T.-C., Cook J.J., Gould R.J., Schaffer L.W., Smith R.L. Nonpeptide fibrinogen receptor antagonists: 7. Design and synthesis of the potent, orally active fibrinogen receptor antagonist L-734,217. J. Med. Chem. 38:1995;3332-3341.
11. a receptor in high risk coronary angioplasty. New Engl. J. Med. 330:1994;956-961.
12. 2 modulate the response to tissue-type plasminogen activator in vivo. Circ. Res. 65:1989;83-94.
13. Foster M.R., Hornby E.J., Brown S., Hann M., Kitchin J., Pike N., Ward P. Inhibition of human platelet aggregation by GR91669, a prototype fibrinogen receptor antagonist. Thromb. Res. 75:1994;269-284.
14. Genetta T.B., Mauro V.F. Abciximab: a new antiaggregant used in angioplasty. Ann. Pharmacother. 30:1996;251-257.
15. Gresele P., Deckmyn H., Nenci G.G., Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. TiPS. 12:1991;158-163.
16. Grotemeyer K.H., Scharafinski H.W., Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb. Res. 71:1993;397-403.
17. a receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo. J. Cardiovasc. Pharmacol. 30:1997;261-272.
18. 2, ADP and thrombin in thrombogenesis in the guinea pig. Eur. J. Pharmacol. 231:1993;421-425.
19. Hirsh P.D., Hillis L.D., Campbell W.B., Firth B.G., Willerson J.T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. New Engl. J. Med. 304:1981;685-691.
20. 1 and argatroban. J. Pharmacol. Exp. Ther. 277:1996;502-510.
21. a antagonist, on arterial thrombosis in guinea-pigs, dogs, and monkeys. Thromb. Res. 86:1997;275-285.
22. a inhibitors: 5. Antithrombotic effects of MK-0383. J. Pharmacol. Exp. Ther. 272:1995;20-32.
23. a receptor antagonist; DMP754: receptor binding affinity and specificity. Coronary Artery Dis. 7:1996;767-774.
24. a antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation. 96:1997;1130-1138.
25. Nicholson N.S., Panzer-Knodle S.G., Salyers A.K., Taite B.B., Szalony J.A., Haas N.F., King L.W., Zablocki J.A., Keller B.T., Broschat K., Engleman V.W., Herin M., Jacqmin P., Feigen L.P. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation. 91:1995;403-410.
26. Okumura K., Shimazaki T., Aoki Y., Yamashita H., Tanaka E., Banba S., Yazawa K., Kibayashi K., Banno H. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of a N-alkylated amidines with a 6,6-bicyclic template. J. Med. Chem. 41:1998;4036-4052.
27. Patrono C. Aspirin as an antiplatelet drug. New Engl. J. Med. 330:1994;1287-1294.
28. Phillips D.R., Charo I.F., Parise L.V., Fitzgerald L.A. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 71:1988;831-843.
29. Phillips, D.R., Fitzgerald, L., Parise, L., Steiner, B., 1992. Platelet membrane glycoprotein IIb-IIIa complex: purification, characterization, and reconstitution into phospholipid vesicles. In: Hawiger, J.J. (Ed.), Methods in Enzymology, Vol. 215, Platelets: Receptors, Adhesion, Secretion. Academic, San Diego, CA, pp. 244-263.
30. 2+ influx into stimulated platelets. Blood. 66:1985;734-761.
31. Rybak M.E.M., Renzulli L.A. Effect of calcium channel blockers on platelet GPIIb-IIIa as a calcium channel in liposomes: comparison with effects on the intact platelet. Thromb. Haemost. 67:1992;131-136.
32. Sandercock P. Antiplatelet therapy with aspirin in acute ischeamic stroke. Thromb. Haemost. 78:1997;180-182.
33. a receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation. 94:1996;2083-2089.
34. a integrin blockade: a randomized, placebo-controlled pilot study of Xemilofiban in unstable angina with percutaneous coronary interventions. Circulation. 96:1997;76-81.
35. Takiguchi Y., Hirata Y., Wada K., Nakashima M. Arterial thrombosis model with photochemical reaction in guinea-pig and its property. Thromb. Res. 67:1992;435-445.
36. 2 in reocclusion after thrombolysis. Thromb. Haemost. 73:1995;683-688.
37. a blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
38. a antagonism in unstable angina: the Canadian Lamifiban study. Circulation 94, 899-905.
39. a. Circulation. 91:1995;1354-1362.
40. 2 receptor antagonist, vapiprost, in rat middle cerebral artery thrombosis model. Stroke. 24:1993;1077-1081.